News

Different Pseudomonas Varieties Found in CF Patient Lungs

Newly found workings of Pseudomonas aeruginosa may explain why certain medications are only modestly effective in patients with cystic fibrosis. A group of researchers led by Dr. Pradeep Singh and Dr. Peter Jorth at the University of Washington School of Medicine discovered that when P. aeruginosa infects cystic fibrosis patients’…

Recipients of the Vertex Science Leaders Scholarship Announced

Global biotechnology company and Cystic Fibrosis therapeutic leader Vertex, together with the University of Massachusetts (UMass), recently revealed the awardees of the yearly Vertex Science Leaders Scholarship, which will fund 4 years of their education in any Science, Technology, Engineering and Math (STEM) course at any UMass campus. This scholarship is part…

CF Foundation’s RDP Expands to Denver and Atlanta

The CF Foundation’s Cystic Fibrosis Research Development Program (RDP) recently expanded its network to include new CF centers in Denver and Atlanta, two cities that house the two largest CF treatment centers in the country. The new RDP in Denver, Colorado will be awarded to $2.1 million in funding, to be…

TORPEDO-CF Clinical Trial Seeks Participants for Antibiotic Study

Patients living with cystic fibrosis (CF) are at increased risk for acquiring and developing severe respiratory infections. The most worrisome pathogen is Pseudomonas aeruginosa (PsA), which is treated with powerful antibiotics either via oral, intravenous, or inhaled antibiotics. While these treatments are known to work, there has yet to be a conclusive…

La Jolla Pharmaceutical Acquires Rights to Gentamicin Derivatives for CF, Other Genetic Diseases

La Jolla Pharmaceutical Company has just announced it has entered two exclusive licensing agreements with the Indiana University Research and Technology Corporation (IURTC), and the IURTC and the University of Alabama at Birmingham (UAB). The agreements cover intellectual property rights for the company’s next-gen gentamicin derivatives, LJPC-30Sa and LJPC-30Sb, as antimicrobial agents…